ArticleSaudi medical journal2026
A Retrospective Review of Antimicrobial Usage and Indications at End-of-Life for Oncology Patients in a Tertiary Cancer Center in Saudi Arabia.
Article in Saudi medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate antimicrobial usage patterns, indications, and outcomes in end-of-life (EOL) oncology patients at Princess Noorah Oncology Center (PNOC), King Abdulaziz Medical City, Jeddah, Saudi Arabia. The use of antimicrobials in oncology patients in EOL care has raised concerns about their appropriateness and the increasing issue of antimicrobial resistance. Methods: The study is a retrospective chart review of cancer patients treated at the PNOC from January 1, 2017, to January 31, 2022. The inclusion criteria included cancer patients ≥18 years who died during their admission. The exclusion criteria included subjects who did not meet the inclusion criteria. Results: Among the 503 patients analyzed, 89.7% received antimicrobial treatment. In 66.5% of cases, the antimicrobial prescriptions were justified by positive culture results, whereas 33.5% were administered without culture confirmation. The most used antimicrobials were Piperacillin-Tazobactam (20.2%) and Vancomycin (11.4%). Antimicrobial use was significantly associated with patient awareness of their diagnosis ( Conclusions: The study highlights the prevalent use of antimicrobials for oncology patients in EOL care, with 89.7% taking antimicrobials. The findings emphasize the need for strong antimicrobial stewardship programs to optimize antimicrobial prescription, aiming to decrease antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.